Bayer AG brought in a new sales team specifically to promote Kerendia (finerenone) in the US for chronic kidney disease (CKD) in patients with type 2 diabetes, and those representatives will hit the ground running later this month. The US Food and Drug Administration approved the non-steroidal mineralocorticoid receptor antagonist on 9 July and the company is working to manufacture enough of the once-daily pills to distribute the product to retail pharmacies within the next two weeks.
Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with type 2 diabetes (T2D). Bayer’s sales team will focus initial promotional efforts on awareness of earlier CKD testing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
